Cash/Burn From SEC Filing For Period: 

Q1 '20

AMRN

Amarin Corporation

Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids.

Cash

$542.2M

Burn Rate

-$20.6M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Vascepa

Cardiovascular disease (triglyceride lowering)

Approved (Quarterly Sales)

Q2 2020

Vascepa

Cardiovascular Disease / Triglycerides

Approved (litigation)

ANDA litigation (Filing Appeal/ Hearing in Q3 or Q4 2020)

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon